Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Purpose Amplification or over-expression of the mitotic Aurora A kinase (AAK) has been reported in several heme-lymphatic malignancies. MLN8237 (alisertib) is a novel inhibitor of AAK that is being developed for the treatment of advanced malignancies. The objectives of this phase I study were to est...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045308/
https://www.ncbi.nlm.nih.gov/pubmed/24352795
http://dx.doi.org/10.1007/s10637-013-0050-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045308/
https://www.ncbi.nlm.nih.gov/pubmed/24352795
http://dx.doi.org/10.1007/s10637-013-0050-9

Ejemplares similares